.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a typical consequence of 11 months, patients along with metastatic stomach cysts who received biomarker-matched treatments based on flowing lump DNA profiling presented a greater clinical benefit than those acquiring unequaled treatment.